AMGN Jun 2024 320.000 call
| Previous close | 1.7000 |
| Open | 1.7200 |
| Bid | 1.8800 |
| Ask | 2.0400 |
| Strike | 320.00 |
| Expiry date | 2024-06-21 |
| Day's range | 1.7200 - 1.7200 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.32k |
PR NewswireAMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)
Amgen (NASDAQ:AMGN) today announced positive topline results from its randomized, double-blind, multicenter, placebo-controlled Phase 3 clinical trial (NCT04540497) evaluating the efficacy and safety of UPLIZNA® (inebilizumab-cdon) for the treatment of Immunoglobulin G4-related disease (IgG4-RD).
Investor's Business DailyDow Jones Biotech Amgen, Netflix, Robinhood, Spotify In Bullish Chart Setups
Dow Jones biotech leader Amgen, along with streaming giant Netflix and Spotify, are in or near buy zones in today's stock market.
PR NewswireAMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:00 a.m. ET on Thursday, June 6, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, and Ian Thompson, senior vice president, U.S. Business Operations at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
